1. Stem Cell/Wnt PI3K/Akt/mTOR Cell Cycle/DNA Damage Autophagy Anti-infection
  2. Organoid PI3K Polo-like Kinase (PLK) Autophagy Antibiotic
  3. Wortmannin

Wortmannin  (Synonyms: 渥曼青霉素; SL-2052; KY-12420)

目录号: HY-10197 纯度: 99.85%
COA 产品使用指南

Wortmannin (SL-2052) 是一种有效的,不可逆的,选择性PI3K 抑制剂,IC50 值为 3 nM。Wortmannin (SL-2052) 阻断自噬 (autophagy) 形成,并有效抑制 Polo-like kinase 1 (PlK1)Plk3IC50 值分别为 5.8 和 48 nM。

MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

Wortmannin Chemical Structure

Wortmannin Chemical Structure

CAS No. : 19545-26-7

1.  客户无需承担相应的运输费用。

2.  同一机构(单位)同一产品试用装仅限申领一次,同一机构(单位)一年内

     可免费申领三个不同产品的试用装。

3.  试用装只面向终端客户

规格 价格 是否有货 数量
10 mM * 1 mL in DMSO ¥990
In-stock
1 mg ¥342
In-stock
5 mg ¥900
In-stock
10 mg ¥1500
In-stock
50 mg ¥5200
In-stock
100 mg 现货 询价
200 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

Customer Review

Other Forms of Wortmannin:

MCE 顾客使用本产品发表的 118 篇科研文献

WB
Cell Viability Assay

    Wortmannin purchased from MCE. Usage Cited in: Cancer Cell Int. 2023 Apr 16;23(1):68.  [Abstract]

    Wortmannin (1 mM; 24 h) significantly reverses the PCK1-OE-induced increased expression of LC3B II in RKO and SW480 cells.

    Wortmannin purchased from MCE. Usage Cited in: Biopolymers. 2023 Mar 28.

    Wortmannin (2 µM; 2, 4, 6 h) decreases the expression of p-AKT and the ratio of p-AKT/AKT while increases the expression of p-ERK and the ratio of p-ERK/ERK in T84 cells.

    Wortmannin purchased from MCE. Usage Cited in: Biopolymers. 2023 Mar 28.

    Wortmannin (5.0, 10 μM; 24 h) significantly induces cell death in T84 cells.

    Wortmannin purchased from MCE. Usage Cited in: bioRxiv. 2023 Feb 14.

    Both of LY294002 (LY; 30 μM) and Wortmannin (Wort; 50 nM) can downregulate the expression of ACE2 in HPAEpiC cells.

    Wortmannin purchased from MCE. Usage Cited in: Cell Mol Life Sci. 2018 Jul;75(14):2627-2641.  [Abstract]

    RAW264.7 macrophages are pre-treated with the inhibitor of ERK, JNK, P38, P65, and AKT signal pathway.Western blot analyzes the non- and phosphorylation of ERK, JNK, P38, P65, and AKT.

    Wortmannin purchased from MCE. Usage Cited in: Arthritis Res Ther. 2018 Feb 7;20(1):20.  [Abstract]

    Cells preincubated with or without the NF-κB inhibitor PDTC (100 μM), the PI3K inhibitor Wortmannin (3 μg/mL), or DMSO-Control for 2 h. Total protein expression of ABCG2, PDZK1, Akt, p-Akt, and NF-κB p65 determined by western blot analysis. Protein expression normalized to that of GAPDH.
    • 生物活性

    • 纯度 & 产品资料

    • 参考文献

    生物活性

    Wortmannin (SL-2052; KY-12420) is a potent, selective and irreversible PI3K inhibitor with an IC50 of 3 nM. Wortmannin also blocks autophagy formation, and potently inhibits Polo-like kinase 1 (PlK1) and Plk3 with IC50s of 5.8 and 48 nM, respectively[1][2][3].

    IC50 & Target[1][2][3]

    PI3K

    3 nM (IC50)

    DNA-PK

    16 nM (IC50)

    PLK3

    48 nM (IC50)

    ATM

    150 nM (IC50)

    ATR

    1.8 μM (IC50)

    MLCK

    200 nM (IC50)

    Autophagy

     

    细胞效力
    (Cellular Effect)
    Cell Line Type Value Description References
    A549 IC50
    0.22 μM
    Compound: wortmannin
    Inhibition of Plk3 in human A549 cells assessed as casein substrate phosphorylation by Western blot
    Inhibition of Plk3 in human A549 cells assessed as casein substrate phosphorylation by Western blot
    [PMID: 17135248]
    A549 IC50
    11.4 μM
    Compound: 1, wortmannin, Wm
    Antiproliferative activity against human A549 cells after 48 hrs by SRB method
    Antiproliferative activity against human A549 cells after 48 hrs by SRB method
    [PMID: 18630894]
    A549 IC50
    4.28 ng/mL
    Compound: wortmannin
    Cytotoxicity against human A549 cells after 24 hrs by YO-PRO-1 assay
    Cytotoxicity against human A549 cells after 24 hrs by YO-PRO-1 assay
    [PMID: 19138858]
    A549 IC50
    4.28 ng/mL
    Compound: wortmannin
    Cytotoxicity against human A549 cells after 24 hrs by propidium iodide assay
    Cytotoxicity against human A549 cells after 24 hrs by propidium iodide assay
    [PMID: 19138858]
    HeLa IC50
    49 nM
    Compound: wortmannin
    Inhibition of AX-7503 binding to recombinant Plk3 expressed in HeLa cells by Western blot
    Inhibition of AX-7503 binding to recombinant Plk3 expressed in HeLa cells by Western blot
    [PMID: 17135248]
    MCF7 IC50
    > 100 μM
    Compound: Wortmannin
    Cytotoxicity against human MCF7 cells after 72 hrs by MTS/PMS assay
    Cytotoxicity against human MCF7 cells after 72 hrs by MTS/PMS assay
    [PMID: 23040731]
    Sf9 IC50
    0.012 μM
    Compound: (+)-2
    Inhibition of human PI3Kalpha expressed in Sf9 cells by fluorescent polarization assay
    Inhibition of human PI3Kalpha expressed in Sf9 cells by fluorescent polarization assay
    [PMID: 21121631]
    体外研究
    (In Vitro)

    Wortmannin(0-100 nM;24-72 小时)以时间和剂量依赖性方式抑制 K562 细胞增殖。24 小时、48 小时和 72 小时的 IC50 值分别为 25±0.10 nM、12.5±0.08 nM 和 6.25±0.11 nM[4]。 Wortmannin 可阻止 YAP 进入核[6]

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Cell Proliferation Assay[4]

    Cell Line: K562 cells
    Concentration: 0, 6.25, 12.5, 25, 50 and 100 nM
    Incubation Time: 0, 24, 48 and 72 hours
    Result: Inhibited the K562 cells proliferation. The IC50 value at 24 hour, 48 hour, and 72 hour was 25±0.10 nM, 12.5±0.08 nM, and 6.25±0.11 nM.
    体内研究
    (In Vivo)

    Wortmannin(口服管饲法;每日;在 Scid 小鼠中;一组八只小鼠在全部 14 天内均以 1 mg/kg 的剂量服用 Wortmannin。第二组八只小鼠在前 5 天以 1.5 mg/kg 的剂量服用 Wortmannin,其余治疗期间剂量减少至 1 mg/kg)治疗显著减缓了小鼠 C3H 乳腺肿瘤和人类 MCF-7 乳腺癌异种移植瘤的生长速度。与对照组相比,7 天 1 mg/kg Wortmannin 可使已患小鼠 C3H 乳腺肿瘤的小鼠的肿瘤负担减少 54%。从肿瘤植入后 1 天开始,连续 14 天服用 1 mg/kg Wortmannin 后,人类 MCF-7 乳腺癌异种移植瘤负担与对照组相比减少了 97%[5]

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: Scid mice with the murine C3H mammary tumor or human MCF-7 breast cancer xenograft[5]
    Dosage: 1 mg/kg and 1.5 mg/kg
    Administration: Oral gavage; daily; one group 1 mg/kg for 14 days; second group 1.5 mg/kg for 5 days then 1.0 mg/kg for 9 days.
    Result: The growth rate of the treated tumors was significantly slower during drug administration than that of nontreated tumors.
    分子量

    428.43

    Formula

    C23H24O8

    CAS 号
    性状

    固体

    颜色

    White to yellow

    中文名称

    渥曼青霉素;沃氏篮酶素;奥特曼宁

    初始来源
    运输条件

    Room temperature in continental US; may vary elsewhere.

    储存方式
    Powder -20°C 3 years
    4°C 2 years
    In solvent -80°C 2 years
    -20°C 1 year
    溶解性数据
    细胞实验: 

    DMSO 中的溶解度 : ≥ 50 mg/mL (116.71 mM; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

    * "≥" means soluble, but saturation unknown.

    配制储备液
    浓度 溶剂体积 质量 1 mg 5 mg 10 mg
    1 mM 2.3341 mL 11.6705 mL 23.3410 mL
    5 mM 0.4668 mL 2.3341 mL 4.6682 mL
    查看完整储备液配制表

    * 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
    储备液的保存方式和期限:-80°C, 2 years; -20°C, 1 year。-80°C储存时,请在2年内使用, -20°C储存时,请在1年内使用。

    • 摩尔计算器

    • 稀释计算器

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    质量
    =
    浓度
    ×
    体积
    ×
    分子量 *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    浓度 (start)

    C1

    ×
    体积 (start)

    V1

    =
    浓度 (final)

    C2

    ×
    体积 (final)

    V2

    动物实验:

    请根据您的 实验动物和给药方式 选择适当的溶解方案。

    以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:
    ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用
    以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

    • 方案 一

      请依序添加每种溶剂: 10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: 2.08 mg/mL (4.85 mM); 悬浊液; 超声助溶

      此方案可获得 2.08 mg/mL的均匀悬浊液,悬浊液可用于口服和腹腔注射。

      1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;再向上述体系中加入 50 μL Tween-80,混合均匀;然后再继续加入 450 μL 生理盐水 定容至 1 mL

      生理盐水的配制:将 0.9 g 氯化钠,溶解于 ddH₂O 并定容至 100 mL,可以得到澄清透明的生理盐水溶液。
    • 方案 二

      请依序添加每种溶剂: 10% DMSO    90% (20% SBE-β-CD in Saline)

      Solubility: ≥ 2.08 mg/mL (4.85 mM); 澄清溶液

      此方案可获得 ≥ 2.08 mg/mL(饱和度未知)的澄清溶液。

      1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液 中,混合均匀。

      2 g SBE-β-CD(磺丁基醚 β-环糊精)粉末定容于 10 mL 的生理盐水中,完全溶解至澄清透明。
    动物溶解方案计算器
    请输入动物实验的基本信息:

    给药剂量

    mg/kg

    动物的平均体重

    g

    每只动物的给药体积

    μL

    动物数量

    由于实验过程有损耗,建议您多配一只动物的量
    请输入您的动物体内配方组成:
    %
    DMSO +
    +
    %
    Tween-80 +
    %
    Saline
    如果您的动物是免疫缺陷鼠或者体弱鼠,建议 DMSO 中的在最后工作液体系中的占比尽量不超过 2%。
    方案所需 助溶剂 包括:DMSO ,均可在 MCE 网站选购。 Tween 80,均可在 MCE 网站选购。
    计算结果
    工作液所需浓度 : mg/mL
    储备液配制方法 : mg 药物溶于 μL  DMSO(母液浓度为 mg/mL)。
    您所需的储备液浓度超过该产品的实测溶解度,以下方案仅供参考,如有需要,请与 MCE 中国技术支持联系。
    动物实验体内工作液的配制方法 : 取 μL DMSO 储备液,加入 μL  μL ,混合均匀至澄清,再加 μL Tween 80,混合均匀至澄清,再加 μL 生理盐水
    连续给药周期超过半月以上,请谨慎选择该方案。
    请确保第一步储备液溶解至澄清状态,从左到右依次添加助溶剂。您可采用超声加热 (超声清洗仪,建议频次 20-40 kHz),涡旋吹打等方式辅助溶解。
    纯度 & 产品资料

    纯度: 99.86%

    参考文献

    完整储备液配制表

    * 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
    储备液的保存方式和期限:-80°C, 2 years; -20°C, 1 year。-80°C储存时,请在2年内使用, -20°C储存时,请在1年内使用。

    可选溶剂 浓度 溶剂体积 质量 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 2.3341 mL 11.6705 mL 23.3410 mL 58.3526 mL
    5 mM 0.4668 mL 2.3341 mL 4.6682 mL 11.6705 mL
    10 mM 0.2334 mL 1.1671 mL 2.3341 mL 5.8353 mL
    15 mM 0.1556 mL 0.7780 mL 1.5561 mL 3.8902 mL
    20 mM 0.1167 mL 0.5835 mL 1.1671 mL 2.9176 mL
    25 mM 0.0934 mL 0.4668 mL 0.9336 mL 2.3341 mL
    30 mM 0.0778 mL 0.3890 mL 0.7780 mL 1.9451 mL
    40 mM 0.0584 mL 0.2918 mL 0.5835 mL 1.4588 mL
    50 mM 0.0467 mL 0.2334 mL 0.4668 mL 1.1671 mL
    60 mM 0.0389 mL 0.1945 mL 0.3890 mL 0.9725 mL
    80 mM 0.0292 mL 0.1459 mL 0.2918 mL 0.7294 mL
    100 mM 0.0233 mL 0.1167 mL 0.2334 mL 0.5835 mL
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    您最近查看的产品:

    Your information is safe with us. * Required Fields.

       产品名称:

     

    * 需求量:

    * 客户姓名:

     

    * Email:

    * 电话:

     

    * 公司或机构名称:

       留言给我们:

    Bulk Inquiry

    Inquiry Information

    产品名称:
    Wortmannin
    目录号:
    HY-10197
    需求量: